Using Advances in Neuroimaging to Detect, Understand, and Monitor Disease Progression in Huntington's Disease

Overview

Journal NeuroRx

Specialty Neurology

Date 2005 Feb 18

PMID 15717027

Citations 19

Authors

H D Rosas

A S Feigin

Steven M Hersch

Affiliations

Soon will be listed here.

Abstract

Transgenic mouse models and other screens are being used to identify potential therapeutic agents for use in clinical trials in Huntington's disease (HD). The development of surrogate markers that can be used in clinical therapeutics is an active area of research. Because HD is relatively uncommon and only a portion of available subjects meet inclusion and exclusion criteria, therapeutic trials are limited by the availability of potential subjects as well as the relative insensitivity of the clinical measures used. Neuroimaging methods offer the potential to provide noninvasive, reproducible, and objective methods not only to better understand the disease process but also to follow in clinical studies to determine if a drug is effective in slowing down disease progression or perhaps even in delaying onset. Following is a review of the literature, which highlights the studies that have been published to date.

Citing Articles

How is Big Data reshaping preclinical aging research?.

Fernandez M, Martinez-Romero J, Aon M, Bernier M, Price N, de Cabo R Lab Anim (NY). 2023; 52(12):289-314.

PMID: 38017182 DOI: 10.1038/s41684-023-01286-y.

Assistive Technology for Cognition and Health-related Quality of Life in Huntington's Disease.

van Walsem M, Howe E, Frich J, Andelic N J Huntingtons Dis. 2016; 5(3):261-270.

PMID: 27689618 PMC: 5088402. DOI: 10.3233/JHD-160210.

BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior.

Besusso D, Geibel M, Kramer D, Schneider T, Pendolino V, Picconi B Nat Commun. 2013; 4:2031.

PMID: 23774276 PMC: 3940866. DOI: 10.1038/ncomms3031.

Monitoring Huntington's disease progression through preclinical and early stages.

Tang C, Feigin A Neurodegener Dis Manag. 2012; 2(4):421-435.

PMID: 23243467 PMC: 3519443. DOI: 10.2217/nmt.12.34.

Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.

Kumar A, Kneynsberg A, Tucholski J, Perry G, van Groen T, Detloff P Exp Neurol. 2012; 237(1):78-89.

PMID: 22698685 PMC: 3418489. DOI: 10.1016/j.expneurol.2012.05.015.

References

Mazziotta J, Phelps M, Pahl J, Huang S, Baxter L, Riege W . Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med. 1987; 316(7):357-62. DOI: 10.1056/NEJM198702123160701. View

Pavese N, Andrews T, Brooks D, Ho A, Rosser A, Barker R . Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain. 2003; 126(Pt 5):1127-35. DOI: 10.1093/brain/awg119. View

Aylward E, Codori A, Rosenblatt A, Sherr M, Brandt J, Stine O . Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord. 2000; 15(3):552-60. DOI: 10.1002/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P. View

Kuwert T, Lange H, Langen K, Herzog H, Aulich A, Feinendegen L . Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain. 1990; 113 ( Pt 5):1405-23. DOI: 10.1093/brain/113.5.1405. View

Reddy P, Williams M, Charles V, Garrett L, Whetsell Jr W, Miller G . Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet. 1998; 20(2):198-202. DOI: 10.1038/2510. View

Ghilardi M, Ghez C, Dhawan V, Moeller J, Mentis M, Nakamura T . Patterns of regional brain activation associated with different forms of motor learning. Brain Res. 2000; 871(1):127-45. DOI: 10.1016/s0006-8993(00)02365-9. View

Lawrence A, Weeks R, Brooks D, Andrews T, Watkins L, Harding A . The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain. 1998; 121 ( Pt 7):1343-55. DOI: 10.1093/brain/121.7.1343. View

Sapp E, Schwarz C, Chase K, Bhide P, Young A, Penney J . Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol. 1997; 42(4):604-12. DOI: 10.1002/ana.410420411. View

Hayden M, Hewitt J, Stoessl A, Clark C, Ammann W, Martin W . The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology. 1987; 37(9):1441-7. DOI: 10.1212/wnl.37.9.1441. View

10.

Backman L, Farde L . Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. Scand J Psychol. 2001; 42(3):287-96. DOI: 10.1111/1467-9450.00238. View

11.

Kremer B, Goldberg P, Andrew S, Theilmann J, Telenius H, Zeisler J . A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994; 330(20):1401-6. DOI: 10.1056/NEJM199405193302001. View

12.

Thieben M, Duggins A, Good C, Gomes L, Mahant N, Richards F . The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain. 2002; 125(Pt 8):1815-28. DOI: 10.1093/brain/awf179. View

13.

Young A, Penney J, Markel D, Berent S, Rothley J, Betley A . Normal caudate glucose metabolism in persons at risk for Huntington's disease. Arch Neurol. 1987; 44(3):254-7. DOI: 10.1001/archneur.1987.00520150010010. View

14.

Kuhl D, Phelps M, Markham C, Metter E, Riege W, Winter J . Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann Neurol. 1982; 12(5):425-34. DOI: 10.1002/ana.410120504. View

15.

Chen M, Ona V, Li M, Ferrante R, Fink K, Zhu S . Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000; 6(7):797-801. DOI: 10.1038/77528. View

16.

Trottier Y, Devys D, Imbert G, Saudou F, An I, Lutz Y . Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet. 1995; 10(1):104-10. DOI: 10.1038/ng0595-104. View

17.

Kunig G, Leenders K, Sanchez-Pernaute R, Antonini A, Vontobel P, Verhagen A . Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. Ann Neurol. 2000; 47(5):644-8. View

18.

Lawrence A, Sahakian B, Hodges J, Rosser A, Lange K, Robbins T . Executive and mnemonic functions in early Huntington's disease. Brain. 1996; 119 ( Pt 5):1633-45. DOI: 10.1093/brain/119.5.1633. View

19.

Clark V, Lai S, Deckel A . Altered functional MRI responses in Huntington's disease. Neuroreport. 2002; 13(5):703-6. DOI: 10.1097/00001756-200204160-00033. View

20.

Young A, Penney J, Markel D, Berent S, Giordani B, Ehrenkaufer R . PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986; 20(3):296-303. DOI: 10.1002/ana.410200305. View